DK3509591T3 - Nye jak1-selektive inhibitorer og anvendelser deraf - Google Patents
Nye jak1-selektive inhibitorer og anvendelser deraf Download PDFInfo
- Publication number
- DK3509591T3 DK3509591T3 DK17858944.6T DK17858944T DK3509591T3 DK 3509591 T3 DK3509591 T3 DK 3509591T3 DK 17858944 T DK17858944 T DK 17858944T DK 3509591 T3 DK3509591 T3 DK 3509591T3
- Authority
- DK
- Denmark
- Prior art keywords
- new
- selective inhibitors
- jak1 selective
- jak1
- inhibitors
- Prior art date
Links
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 title 1
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662403660P | 2016-10-03 | 2016-10-03 | |
| PCT/US2017/054668 WO2018067422A1 (en) | 2016-10-03 | 2017-09-30 | Novel jak1 selective inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3509591T3 true DK3509591T3 (da) | 2021-12-20 |
Family
ID=61831161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17858944.6T DK3509591T3 (da) | 2016-10-03 | 2017-09-30 | Nye jak1-selektive inhibitorer og anvendelser deraf |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10738060B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3509591B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7089141B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102399848B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN108366994B (cg-RX-API-DMAC7.html) |
| AU (3) | AU2017339417C1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3509591T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201990523A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2901216T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1253040A1 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20211965T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE058120T2 (cg-RX-API-DMAC7.html) |
| IL (3) | IL265358B (cg-RX-API-DMAC7.html) |
| MX (1) | MX390005B (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ751284A (cg-RX-API-DMAC7.html) |
| PL (1) | PL3509591T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3509591T (cg-RX-API-DMAC7.html) |
| RS (1) | RS62695B1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018067422A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62695B1 (sr) | 2016-10-03 | 2022-01-31 | Highlightll Pharmaceutical Hainan Co Ltd | Novi jak1 selektivni inhibitori i njihove upotrebe |
| PL3568396T3 (pl) | 2017-01-11 | 2021-05-31 | Leo Pharma A/S | Nowe pochodne aminoimidazopirydyny jako inhibitory kinaz janusowych i ich zastosowanie farmaceutyczne |
| EA202191170A1 (ru) * | 2018-10-31 | 2021-07-27 | Инсайт Корпорейшн | Комбинированная терапия для лечения гематологических заболеваний |
| IL285999B1 (en) * | 2019-03-05 | 2025-09-01 | Incyte Corp | JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction |
| TW202102222A (zh) * | 2019-03-19 | 2021-01-16 | 美商英塞特公司 | 白斑病之生物標記物 |
| BR112021024530A2 (pt) | 2019-06-06 | 2022-01-18 | Highlightll Pharmaceutical Hainan Co Ltd | Método para sintetizar composto de furoimidazopiridina, substância polimórfica e substância polimórfica de sal |
| KR20240100424A (ko) | 2019-06-06 | 2024-07-01 | 항저우 하이라이트엘엘 파마슈티컬 씨오., 엘티디. | 푸로이미다조피리딘 화합물의 합성 방법, 푸로이미다조피리딘 화합물의 결정 형태, 및 그의 염의 결정 형태 |
| BR112022023550A2 (pt) | 2020-05-19 | 2023-01-03 | Bayer Cropscience Ag | (tio)amidas azabicíclicas como compostos fungicidas |
| CN116057056B (zh) | 2020-06-10 | 2025-09-19 | 拜耳公司 | 作为杀真菌剂的氮杂双环取代的杂环化合物 |
| WO2022260945A1 (en) * | 2021-06-07 | 2022-12-15 | The Regents Of The University Of California | Compositions and methods for treating celiac disease |
| CN118059096A (zh) * | 2021-09-13 | 2024-05-24 | 杭州高光制药有限公司 | 治疗cns病症的方法 |
| CN114213424B (zh) | 2021-12-30 | 2023-05-26 | 杭州高光制药有限公司 | 一种呋喃[3，2-b]并吡啶衍生物的合成方法 |
| WO2025224600A1 (en) * | 2024-04-21 | 2025-10-30 | Biohaven Therapeutics Ltd. | Treatment of alpha-synucleinopathies and neuroprotection |
| WO2025248468A1 (en) | 2024-05-28 | 2025-12-04 | Biohaven Therapeutics Ltd. | Use of tyk2/jak1 inhibitors to treat amyloid-related imaging abnormalities (aria) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| EP0188040B1 (en) | 1985-01-11 | 1991-08-14 | Abbott Laboratories Limited | Slow release solid preparation |
| JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
| UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| ATE292961T1 (de) | 1998-07-28 | 2005-04-15 | Tanabe Seiyaku Co | Zur wirkstoffabgabe an zielorten im darm fähige zubereitung |
| JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | １ｈ―イミダゾピリジン誘導体 |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US6800663B2 (en) | 2002-10-18 | 2004-10-05 | Alkermes Controlled Therapeutics Inc. Ii, | Crosslinked hydrogel copolymers |
| JP2007526324A (ja) | 2004-03-02 | 2007-09-13 | スミスクライン・ビーチャム・コーポレイション | Ａｋｔ活性のある阻害剤 |
| CN101277965A (zh) * | 2005-08-04 | 2008-10-01 | 西特里斯药业公司 | 作为SIRTUIN调节化合物的咪唑并[2,1-b]噻唑衍生物 |
| CN102741253A (zh) * | 2009-09-29 | 2012-10-17 | 艾科睿控股公司 | PI3K(δ)选择性抑制剂 |
| WO2012022045A1 (en) * | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| PH12013500661A1 (en) * | 2010-10-08 | 2017-08-23 | Abbvie Inc | FURO[3,2-d]PYRIMIDINE COMPOUNDS |
| WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| PH12013502670A1 (en) | 2011-08-12 | 2016-07-29 | Nissan Chemical Ind Ltd | Tricyclic heterocyclic compounds and jak inhibitors |
| AR093308A1 (es) | 2012-11-01 | 2015-05-27 | Incyte Corp | Derivados triciclicos fusionados de tiofeno como inhibidores de jak |
| CA2926361A1 (en) | 2013-10-24 | 2015-04-30 | Abbvie Inc. | Jak1 selective inhibitor and uses thereof |
| PE20170300A1 (es) | 2014-04-30 | 2017-04-19 | Incyte Corp | Procesos para preparar un inhibidor de jak 1 y nuevas formas de este |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| RS62695B1 (sr) | 2016-10-03 | 2022-01-31 | Highlightll Pharmaceutical Hainan Co Ltd | Novi jak1 selektivni inhibitori i njihove upotrebe |
-
2017
- 2017-09-30 RS RS20211521A patent/RS62695B1/sr unknown
- 2017-09-30 JP JP2019517991A patent/JP7089141B2/ja active Active
- 2017-09-30 MX MX2019003649A patent/MX390005B/es unknown
- 2017-09-30 HU HUE17858944A patent/HUE058120T2/hu unknown
- 2017-09-30 NZ NZ751284A patent/NZ751284A/en unknown
- 2017-09-30 PT PT178589446T patent/PT3509591T/pt unknown
- 2017-09-30 EA EA201990523A patent/EA201990523A1/ru unknown
- 2017-09-30 PL PL17858944T patent/PL3509591T3/pl unknown
- 2017-09-30 KR KR1020197009016A patent/KR102399848B1/ko active Active
- 2017-09-30 CN CN201780004442.5A patent/CN108366994B/zh active Active
- 2017-09-30 ES ES17858944T patent/ES2901216T3/es active Active
- 2017-09-30 HK HK18112420.5A patent/HK1253040A1/zh unknown
- 2017-09-30 US US16/333,994 patent/US10738060B2/en not_active Ceased
- 2017-09-30 DK DK17858944.6T patent/DK3509591T3/da active
- 2017-09-30 HR HRP20211965TT patent/HRP20211965T1/hr unknown
- 2017-09-30 WO PCT/US2017/054668 patent/WO2018067422A1/en not_active Ceased
- 2017-09-30 AU AU2017339417A patent/AU2017339417C1/en active Active
- 2017-09-30 CN CN202110514751.5A patent/CN113214278B/zh active Active
- 2017-09-30 US US17/526,799 patent/USRE49834E1/en active Active
- 2017-09-30 EP EP17858944.6A patent/EP3509591B1/en active Active
-
2019
- 2019-03-13 IL IL265358A patent/IL265358B/en unknown
-
2022
- 2022-02-17 AU AU2022201058A patent/AU2022201058B2/en active Active
- 2022-02-17 AU AU2022201061A patent/AU2022201061B2/en active Active
- 2022-03-10 IL IL291265A patent/IL291265B2/en unknown
- 2022-03-10 IL IL291267A patent/IL291267B2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3509591T3 (da) | Nye jak1-selektive inhibitorer og anvendelser deraf | |
| DK3658557T3 (da) | Tyk2-inhibitorer og anvendelser deraf | |
| EP3526222A4 (en) | TYK2 INHIBITORS AND THEIR USES | |
| EP3528816A4 (en) | TYK2 INHIBITORS AND USES THEREOF | |
| DK3389658T3 (da) | Glycosidasehæmmere og anvendelser deraf | |
| HUE061064T2 (hu) | Szelektív JAK1 gátlók | |
| IL280863A (en) | Autotaxin inhibitors and uses thereof | |
| DK3436048T3 (da) | Neoantigener og fremgangsmåder til anvendelse deraf | |
| DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
| DK3160966T3 (da) | Mnk-inhibitorer og fremgangsmåder forbundet dermed | |
| DK3302431T3 (da) | Taxanpartikler og anvendelse deraf | |
| DK3365339T3 (da) | Nye ferroportin-hæmmere | |
| DK3172213T3 (da) | Makrocykliske kinasehæmmere og anvendelser deraf | |
| DK3516160T3 (da) | Brøndanordning og tilhørende fremgangsmåder | |
| EP4358558C0 (en) | APPARATUS AND METHOD FOR CAPACITY RATIO | |
| DK3193611T3 (da) | Mk2-inhibitorer og anvendelser deraf | |
| DK3555076T3 (da) | Nye phenylpropionsyrederivater og anvendelser deraf | |
| DK3356558T3 (da) | Sirs patogenbiomarkører og anvendelser deraf | |
| DK3474883T3 (da) | Komplementinhibitorer og anvendelser deraf | |
| DK3621694T3 (da) | Lrrc33-inhibitorer og anvendelse heraf | |
| DK3543240T3 (da) | URAT1-inhibitor og anvendelse deraf | |
| DK3447056T3 (da) | Multikinasehæmmerforbindelse, krystalform og anvendelse deraf | |
| DK3426243T3 (da) | 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf | |
| DK3532459T3 (da) | Lsd1-hæmmere og medicinske anvendelser deraf | |
| DK3321279T3 (da) | Exenatidmodificeringsmiddel og anvendelse deraf |